Evotec AG (EVTCV)

[surf1944]

Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
stay away until this merger is complete, this type is never good for current shareholders
Thursday April 3, 4:05 pm ET

SOUTH SAN FRANCISCO, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired without the United States Federal Trade Commission requesting additional information with regard to the pending acquisition of Renovis by Evotec AG (EVT.DE).

The companies anticipate that the transaction, which remains subject to the approval of Renovis's stockholders and other customary closing conditions, will close in early May, 2008.

About Renovis

Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1).